Filtered By:
Condition: Heart Valve Disease

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 554 results found since Jan 2013.

Novel anticoagulants in patients with mechanical heart valves
Commentary on: Eikelboom JW, Connolly SJ, Brueckmann M, et al.. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013;369:1206. Context Novel anticoagulants (including the direct thrombin inhibitor dabigatran etixilate) and oral factor Xa inhibitors have similar or superior efficacy and safety to warfarin for reducing thromboembolic stroke in patients with atrial fibrillation, and for prevention of deep venous thrombosis. Eikelboom and colleagues set out to examine whether these novel anticoagulants could be used as an alternative to warfarin in patients with mechanical heart valves. Method...
Source: Evidence-Based Medicine - May 19, 2014 Category: Internal Medicine Authors: Stewart, R. A. H. Tags: Drugs: cardiovascular system, Stroke, Venous thromboembolism Therapeutics Source Type: research

Risk Stratification and Stroke Prevention Therapy Care Gaps in Canadian Atrial Fibrillation Patients (From the CO-ordinated National Network to Engage physicians in the Care and Treatment of patients with Atrial Fibrillation CONNECT AF Chart Audit)
The objectives of this national chart audit (January-June 2013) of 6346 AF patients (≥18 years without a significant heart valve disorder) from 647 primary care physicians were to: 1) Describe the frequency of stroke and bleed risk assessments in patients with non-valvular atrial fibrillation (AF) by primary care physicians, including the accuracy of these assessments relative to established predictive indices; 2) outline contemporary methods of anticoagulation used; and, 3) report the time in the therapeutic range amongst patients prescribed warfarin.
Source: The American Journal of Cardiology - December 17, 2014 Category: Cardiology Authors: Ashish D. Patel, Mary K. Tan, Paul Angaran, Alan D. Bell, Murray Berall, Claudia Bucci, Andrew M. Demchuk, Vidal Essebag, Lianne Goldin, Martin S. Green, Jean C. Gregoire, Peter L. Gross, Brett Heilbron, Peter J. Lin, Krishnan Ramanathan, Allan Skanes, Br Source Type: research

Low mortality, stroke seen with newest Edwards TAVR system: study
(Reuters) - Researchers on Sunday presented trial data showing very low mortality and stroke rates using the third generation version of Edwards Lifesciences Corp's non-invasive heart valve replacement system that could help support its U.S. approval.
Source: Reuters: Health - March 15, 2015 Category: Consumer Health News Tags: healthNews Source Type: news

Automatic extraction of forward stroke volume using dynamic PET/CT: a dual-tracer and dual-scanner validation in patients with heart valve disease
Background: The aim of this study was to develop and validate an automated method for extracting forward stroke volume (FSV) using indicator dilution theory directly from dynamic positron emission tomography (PET) studies for two different tracers and scanners. Methods: 35 subjects underwent a dynamic 11 C-acetate PET scan on a Siemens Biograph TruePoint-64 PET/CT (scanner I). In addition, 10 subjects underwent both dynamic 15 O-water PET and 11 C-acetate PET scans on a GE Discovery-ST PET/CT (scanner II). The left ventricular (LV)-aortic time-activity curve...
Source: Epidemiologic Perspectives and Innovations - October 26, 2015 Category: Epidemiology Authors: Hendrik HarmsLars TolbodNils HanssonTanja KeroLovisa OrndahlWon KimTomas BjernerKirsten BoucheloucheHenrik WiggersJørgen FrøkiærJens Sörensen Source Type: research

Papillary fibroelastoma originating from the free left ventricular wall as the cause of recurrent stroke: Description of the case and literature review
Publication date: Available online 20 October 2015 Source:Cor et Vasa Author(s): Ondřej Macura, Tomáš Paleček, Jaroslav Hlubocký, Petr Vondráček, Ivana Vítková, Jan Kuchař, Zuzana Hlubocká Papillary fibroelastoma is the third most common primary benign cardiac tumor typically found on the endocardium of heart valves, most often left-heart ones. The authors present the case of a 52-year-old patient experiencing recurrent cardioembolic stroke involving the cerebral arteries secondary to a fibroelastoma originating from the free left ventricular wall and, given its symptomatic nature, indicated for surgical excision.
Source: Cor et Vasa - February 23, 2016 Category: Cardiology Source Type: research

Prosthetic heart valve thrombosis treated with slow infusion fibrinolytic therapy in patient with acute isquemic stroke.
PMID: 27364707 [PubMed - as supplied by publisher]
Source: Archivos de Cardiologia de Mexico - June 26, 2016 Category: Cardiology Authors: Garagoli F, Romeo FJ, Lucas L, Kotowicz V, Belziti C Tags: Arch Cardiol Mex Source Type: research

Keystone Heart, Venus Medtech ink Asian TAVR stroke partnership deal
Keystone Heart and Chinese heart valve maker Venus Medtech said today they inked a partnership deal covering China and other Asian markets. Through the deal, the companies will provide Venus Medtech’s transcatheter aortic valve replacement system along with Keystone’s TriGuard cerebral embolic protection device. TriGuard is a cerebral embolic protection device designed to reduce the amount of embolic material entering blood circulation to the brain during TAVR procedures, by allowing blood to pass through while catching potentially dangerous embolic debris. “Providing brain protection for every TAVR pat...
Source: Mass Device - March 2, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Cardiovascular Catheters Replacement Heart Valves Keystone Heart Venus Medtech Source Type: news

Stroke Related to Transcatheter Heart Valve Thrombosis.
Authors: Hansson NC, Leipsic J, Leetmaa T, Mortensen UM, Andersen HR, Jensen JM, Nørgaard BL PMID: 28290179 [PubMed - in process]
Source: Journal of Heart Valve Disease - March 21, 2017 Category: Cardiology Tags: J Heart Valve Dis Source Type: research

Apixaban for stroke prevention in a patient with a mechanical heart valve.
PMID: 30418836 [PubMed - in process]
Source: British Journal of Hospital Medicine - November 2, 2018 Category: Internal Medicine Authors: Shukla P, Ashraf I, Aghoram P Tags: Br J Hosp Med (Lond) Source Type: research

Asymptomatic Carotid Stenosis Is Associated With Circadian and Other Variability in Embolus Detection
Conclusions: Embolism associated with asymptomatic carotid stenosis shows circadian variation with highest rates 4–6 h before midday. This corresponds with peak circadian incidence of stroke and other vascular complications. These and ASED Study results show that monitoring frequency, duration, and time of day are important in ES detection. Introduction Transcranial Doppler (TCD) detected microembolism in the ipsilateral middle cerebral artery (MCA) may help stratify the risk of stroke and other arterial disease complications in persons with advanced (≥60%) asymptomatic carotid stenosis. If so, this t...
Source: Frontiers in Neurology - April 15, 2019 Category: Neurology Source Type: research

'Nine out of 10 strokes preventable,' claims study
Conclusion This valuable research aims to clarify which preventable risk factors are associated with stroke risk – knowledge that could have an effect on addressing this important global health problem. The study's strengths are that it is based on a large sample size of nearly 27,000 people from 32 countries and of different socioeconomic backgrounds. The researchers made careful attempts beforehand to calculate how many participants they would need to include to be able to reliably detect differences in risk factors. There was little missing data across the total sample – for the various different risk factors as...
Source: NHS News Feed - July 18, 2016 Category: Consumer Health News Tags: Neurology Medication Source Type: news

New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news

FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

New Phase 3 Data Suggest Positive Effect and Show Similar Safety with XARELTO ® (rivaroxaban) Compared to Aspirin in Pediatric Fontan Procedure Patients at Risk for Blood Clots and Blood Clot-Related Events
RARITAN, NJ, September 27, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data from the Phase 3 UNIVERSE study showing treatment with XARELTO® (rivaroxaban) in an oral suspension formulation, compared to treatment with aspirin, was associated with numerically fewer blood clots and clinical events strongly associated with blood clots in pediatric patients (aged 2-8 years) who have undergone the Fontan procedure. [1] These findings, which were published this month in the Journal of the American Heart Association and included in a recent New Drug Application submitted to the U.S. F...
Source: Johnson and Johnson - September 27, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to Tweet: Jan...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news